Full Press Release Details
Engineering the Alpha Advantage in Targeted Oncology
Optimizing the Entire System
Expanding the Addressable Market
Unlocking New Treatment Options Across Solid Tumors:
Choosing The Right Isotope
Optimizing Structural Chemistry:
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
A Decade of Deliberate, End-to-End Engineering
Direct-to-Hospital Delivery through Integrated Isotope Production
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Perspective Therapeutics
Theranostics in management of patients with neuroendocrine and other SSTR positive tumors
Adverse side effects
Other factors that drive treatment
Survival expectations
Treatment decision making
The evolution of the treatment continuum
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT- -NET in NETs
Patient with Confirmed PR After [212Pb]VMT- -NET Treatment
VMT- -NET: Baseline Patient Characteristics in AACR 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT- -NET in AACR 2026 Data Analysis
Blood Creatinine During Follow-up for All Patients Treated (n=64)
VMT- -NET: Durable Disease Control Across All Doses
Spider plot of tumor change over time by patient
VMT- -NET Responses Deepen Over Time
VMT- -NET's Compelling Profile Supports Potential Registration Study at Current Dose Level
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT- -NET in NETs
VMT- -NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
[212Pb]Pb-VMT- -NET after previous radio-ligand treatment
Dresden VMT- -NET compassionate use program
Dresden VMT- -NET compassionate use program
Dresden VMT- -NET compassionate use program
Dresden VMT- -NET compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
Imaging and dosimetry
How biodistribution informs therapeutic potential
Patient's journey from PSA>MRI>PSMA PET
Receptor Targeted PET enabled a fundamentally different clinical trial design: Treat if you see it
68Ga/177Lu-PSMA Super vs Non-Responder
68Ga/177Lu-DOTATATE Super vs Non-Responder
Radioligand Therapy Today Science advances one funeral at a time Max Planck
Radioligand Therapy Today Science advances one funeral at a time Max Planck
FAP is an Emerging Target
Not every FAP is bio-identical
Theranostics Short Half-lives for Long, Full Lives
FIH 203/212Pb Pb-VMT- -NET Perspective Therapeutics
FIH 203/212Pb Pb-VMT- -NET Perspective Therapeutics
Early, Medium and Late Biodistribution Should Inform Therapeutic Window
Perspective's CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa
Development of PSV594 for CCK2R+ Tumor types
CCK2R: Implicated in Multiple Tumor Types With Major Unmet Needs
Expanding the Addressable Market
Optimizing the Entire System
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade:
Advancing a Theranostic Approach:
212Pb is Our Isotope of Choice
Choosing The Right Isotope
Kinetics Matter: 212Pb Hits Hard and Fast For Strong Activity with Less Systemic Exposure
-Particles Delivers More Potent, Targeted Tumor Killing vs. -Particles
212Pb Further Enhanced by Proprietary Chelator for Targeted Delivery of Payload
212Pb Multi-Mechanistic Activity Drives Tumor Destruction and Anti-Tumor Immunity
Rationale for Synergy with Immune Checkpoint Inhibitors
212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors
212Pb Half-life Is More Convenient for Customers
Advancing a Theranostic Approach:
Supply Chain and Manufacturing Infrastructure
End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway
Direct-to-Hospital Delivery through Integrated Isotope Production
Reliable, On-Demand 212Pb from 228Th and 224Ra
Flexible Scalable 224Ra Supply Enables Regional Manufacturing
Ideal for Regional Manufacturing
On-Demand Fulfillment at Regional Sites for Finished Product Delivery
Daily Production at Regional Sites Ensures Supply of Ready-to-administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Mature, Well-Established Distribution Networks
Network Approach Chosen by Novartis